No Data
ST Zhongtai: 2025 First Quarter Report
ST Zhongtai (002092.SZ): A net loss of 89.7979 million yuan in the first quarter.
On April 24, 2023, ST Zhongtai (002092.SZ) announced its Q1 2025 report, the company achieved revenue of 6.767 billion yuan, a year-on-year decrease of 13.02%; the net income attributable to shareholders of the listed company was -89.7979 million yuan; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.106 billion yuan; the basic EPS was -0.0349 yuan.
Special Treat Zhongtai (002092.SZ): In 2024, the export Business accounted for 4.51% of revenue.
On April 17, Gelonghui reported that ST Zhongtai (002092.SZ) stated on the investor interaction platform that the company primarily focuses on domestic sales, with export business accounting for 4.51% of revenue in 2024. The company will continue to monitor changes in the international environment, actively adopt countermeasures, and respond flexibly to the complex and ever-changing external environment.
ST Zhongtai (002092.SZ): The company is actively promoting the Methanol project, which has not yet officially commenced production.
Gelonghui, on April 17, reported that Special Treat Zhongtai (002092.SZ) stated on the investor interactive platform that the company is actively promoting the Methanol project, which has not yet officially started production. The benefits after reaching full production will depend on market conditions, customer Orders, and other factors. Please pay attention to the company's future announcements for specific progress.
ST Zhongtai (002092.SZ): The demonstration project for the comprehensive utilization of New Materials resources to produce Methanol has been successfully completed and handed over.
On April 15, Gelonghui reported that Special Treat Zhongtai (002092.SZ) announced that the recent demonstration project for the resource utilization of New Materials for Methanol has successfully completed the handover, transitioning from the construction phase to the trial production phase.
ST Zhongtai: 2024 Annual Report